Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30098360 | 1.00 | CA12 (0.66) | CA12CA9NPSR1POLBALDH1A1 | |
| SCHEMBL877279 | 0.89 | KMT2A (0.73) | CA12CA9ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL29459522 | 0.89 | KMT2A (0.73) | CA12CA9ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL13537849 | 0.88 | CA12 (0.56) | CA12CA9NPSR1POLBALDH1A1 | |
| SCHEMBL5371377 | 0.88 | CA12 (0.56) | CA12CA9NPSR1POLBALDH1A1 | |
| SCHEMBL1795851 | 0.87 | HDAC8 (0.67) | CA12CA9ALDH1A1KMT2AHSD17B10 | |
| Hydrochloric Acid SCHEMBL9878928 | 0.87 | KMT2A (0.71) | CA12CA9ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL14594063 | 0.86 | KMT2A (0.60) | CA12CA9POLBALDH1A1KMT2A | |
| SCHEMBL3468927 | 0.85 | HDAC8 (0.69) | ALDH1A1KMT2AHSD17B10GAAHPGD | |
| SCHEMBL9899475 | 0.85 | HDAC8 (0.69) | ALDH1A1KMT2AHSD17B10GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530786-A | Film stripping liquid suitable for flexible circuit board and preparation method thereof | 深圳市天熙科技开发有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-114213503-A | Synthesis method of snake venom-like tripeptide | 上海予利生物科技股份有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-108070279-B | Pigment dispersion and coloring composition using phthalimide and derivative thereof | 山阳色素株式会社 | 2021-09-07 | — | — | CN | claimed |
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | claimed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| US-RE32868-E | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1989-02-14 | — | — | US | claimed |
| US-4395417-A | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1983-07-26 | — | — | US | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4605088-A1 | MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| US-20250059184-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| CN-119320809-A | Method for preparing L-carnosine by using yeast whole-cell catalyst | 大连理工大学 | 2025-01-17 | — | — | CN | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| US-4267174-A | AND PROCESS FOR ADMINISTERING | BOEHRINGER MANNHEIM, GMBH (DE) | 1981-05-12 | — | — | US | disclosed |
| US-4230715-A | 1,2,4-Triazole-3-thiols as antisecretory agents | RICHARDSON-MERRELL INC. (US) | 1980-10-28 | — | — | US | disclosed |
| US-4099010-A | PHTHALOYL AMINO ACID HYDROXAMIC ACIDS | MORTON-NORWICH PRODUCTS, INC. (US) | 1978-07-04 | — | — | US | disclosed |
| US-4077998-A | Phthaloyl amino acid hydroxamic acids | MORTON-NORWICH PRODUCTS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4075221-A | ALKYLATION WITH DIALKYLMETHYLENEAMMONIUM SALT IN PRESENCE OF REACTIVE CARBOXYLIC ACYLATING AGENT | THE UPJOHN COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4012413-A | 1-(2-AMINOALKYL)-6-PHENYL-TRIAZOLO-BENZODIAZEPINE COMPOUNDS USED AS TRANQUILIZERS AND ANTIDEPRESSANTS | THE UPJOHN COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
| US-3994940-A | Preparation of 1-(2-(dimethylamino)ethyl)-6-phenyl-4H-5-triazolo(4,3-a)(1,4)benzodiazepines | THE UPJOHN COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | CA12 4281/4885CA9 4354/4885NPSR1 3535/4885 |
| US-20250059184-A1 | IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF | GRIN2A, GAP43, GRIN2C | CA12 4439/4885CA9 4804/4885NPSR1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.